Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YghJ/SslE vaccine - GlyProVac

Next Previous
X
Search
Drug Profile

YghJ/SslE vaccine - GlyProVac

Alternative Names: YghJ vaccine - GlyProVac; YghJ/SslE/AcfD vaccine - GlyProVac

Latest Information Update: 10 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Southern Denmark
  • Class Bacterial vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Urinary tract infections
  • Research Diarrhoea

Most Recent Events

  • 07 Oct 2022 GlyProVac has patent pending for Glycosylated YghJ polypeptides from enterotoxigenic Escherichia coli in USA (GlyProVac website, October 2022)
  • 07 Oct 2022 GlyProVac has patent protection for Glycosylated YghJ polypeptides from enterotoxigenic Escherichia coli in Germany, France, Italy, United Kingdom, Belgium and Denmark and patent pending in USA (GlyProVac website, October 2022)
  • 07 Oct 2022 GlyProVac has patent protection for the BEMAP method for identification of glycosylated YghJ polypeptides from enterotoxigenic Escherichia coli (ETEC) in USA (GlyProVac website, October 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top